Abstract
Introduction: There is a need for effective and safe treatment during pregnancy in women with chronic inflammatory diseases (rheumatoid arthritis/axial spondyloarthritis/psoriatic arthritis/Crohn's disease). Adequate disease control is crucial to reduce the risk of adverse pregnancy outcomes. Anti-TNFs are effective therapies, but because most cross the placenta they are often stopped during pregnancy. Certolizumab pegol (CZP), due to its Fc-free molecular structure, is not expected to undergo placental transfer compared to other anti-TNFs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Obstetrics & Gynecology and Reproductive Biology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
